Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery

JAMA

Volumn 297, Issue 5, 2007, Pages 471-479

  Mangano, Dennis T ^a   Miao, Yinghui ^a   Vuylsteke, Alain ^b   Tudor, Iulia C ^j   Juneja, Rajiv ^c   Filipescu, Daniela ^d   Hoeft, Andreas ^e   Fontes, Manuel L ^f,k   Hillel, Zak ^g   Ott, Elisabeth ^h   Titov, Tatiana ^a   Dietzel, Cynthia ^a   Levin, Jack ⁱ  

^a Ischemia Research and Education Foundation   (United States)

^b PAPWORTH HOSPITAL   (United Kingdom)

^c ESCORTS HEART INSTITUTE AND RESEARCH CENTRE   (India)

^d Institute of Cardiology   (Romania)

^e UNIVERSITY OF BONN   (Germany)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^h LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j ALZA CORPORATION   (United States)

^k WEILL CORNELL MEDICAL COLLEGE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; APROTININ; LYSINE DERIVATIVE; SERINE PROTEINASE INHIBITOR; TRANEXAMIC ACID;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; COVARIANCE; DRUG FATALITY; FEMALE; HAZARD RATIO; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OBSERVATIONAL STUDY; POSTOPERATIVE HEMORRHAGE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL;

EID: 33846885901     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.297.5.471     Document Type: Article

References (55)

1. Mangano DT, Tudor IC, Dietzel C; for the Multicenter Study of Perioperative Ischemia (McSPI) Research Group and the Ischemia Research and Education Foundation. The risk associated with aprotinin in cardiac surgery. N Engl J Med. 2006;354:353-365.
2. US Food and Drug Administration. Meeting of the cardiovascular and renal advisory committee, September 21, 2006. http://www.fda.gov/ohrms/dockets/ac/ cder06.html#CardiovascularRenal. Accessed January 16, 2007.
3. US Food and Drug Administration. Approval of aprotinin, press release 93-48, December 30, 1993. http://www.fda.gov/bbs/topics/NEWS/NEW00453.html. Accessed January 16, 2007.
4. Ad N, Barnett S, Hunt SL, Fitzgerald D, Speir AM; for INOVA Heart and Vascular Institute Falls Church, VA. The use of aprotinin in cardiac surgery is associated with increased risk of renal failure and neurological events [abstract]. Circulation. 2006;114(suppl II):II476.
5. Brown JR, Birkmeyer NJ, O'Connor GT. Aprotinin in cardiac surgery. N Engl J Med. 2006;354:1953-1957.
6. Karkouti K, Beattie WS, Dattilo KM, et al. Blood conservation and transfusion alternatives. Transfusion. 2006;46:327-338.
7. Cooper JR Jr, Abrams J, Frazier OH, et al. Fatal pulmonary microthrombi during surgical therapy for endstage heart failure. J Thorac Cardiovasc Surg. 2006;131:963-968.
8. US Food and Drug Administration. FDA public health advisory aprotinin injection (marketed as Trasylol), FDA alert P06-19, February 8, 2006. http://www.fda.gov/cder/drug/advisory/aprotinin.htm. Accessed January 16, 2007.
9. US Food and Drug Administration. Questions and answers on aprotinin (marketed as Trasylol). http://www.fda.gov/cder/drug/infopage/aprotinin/ aprotininQA.htm. Accessed January 16, 2007.
10. Havel MP, Griesmacher A, Weigel G, et al. Aprotinin decreases release of 6-keto-prostaglandin F1 alpha and increases release of thromboxane B2 in cultured human umbilical vein endothelial cells. J Thorac Cardiovasc Surg. 1992;104:654-658.
11. Hill GE, Taylor JA, Robbins RA. Differing effects of aprotinin and episolon-aminocaproic acid on cytokine-induced inducible nitric oxide synthase expression. Ann Thorac Surg. 1997;63:74-77.
12. Samama CM, Mazoyer E, Bruneval P, et al. Aprotinin could promote arterial thrombosis in pigs. Thromb Haemost. 1994;71:663-669.
13. Ülker S, Pascal P, McKeown P, Bayraktutan U. Aprotinin impairs coronary endothelial function and down-regulates endothelial NOS in rat coronary microvascular endothelial cells. Cardiovasc Res. 2002;55:830-837.
14. Cosgrove DM III, Heric B, Lytle BW, et al. Aprotinin therapy for reoperative myocardial revascularization. Ann Thorac Surg. 1992;54:1031-1038.
15. Saffitz JE, Stahl DJ, Sundt TM, Wareing TH, Kouchoukos NT. Disseminated intravascular coagulation after administration of aprotinin in combination with deep hypothermic circulatory arrest. Am J Cardiol. 1993;72:1080-1082.
16. Alderman EL, Levy JH, Rich JB. Analyses of coronary graft patency after aprotinin use. J Thorac Cardiovasc Surg. 1998;116:716-730.
17. Alvarez JM, Chandraratna H, Newman MA, Levy JH. Case 3-1999: intraoperative coronary thrombosis in association with low-dose aprotinin therapy. J Cardiothorac Vasc Anesth. 1999;13:623-628.
18. Rodriguez A, Boullon F, Perez-Balino N, et al. Argentine randomized trial of percutaneous transluminal coronary angioplasty vs coronary artery bypass surgery in multivessel disease (ERACI). J Am Coll Cardiol. 1993;22:1060-1067.
19. King SB III, Lembo NJ, Weintraub WS, et al. A randomized trial comparing coronary angioplasty with coronary bypass surgery. N Engl J Med. 1994;331:1044-1050.
20. CABRI Trial Participants. First-year results of CABRI (Coronary Angioplasty vs Bypass Revascularisation Investigation). Lancet. 1995;346:1179-1184.
21. Fitzgibbon GM, Kafka HP, Leach AJ, et al. Coronary bypass graft fate and patient outcome. J Am Coll Cardiol. 1996;28:616-626.
22. The Writing Group for the Bypass Angioplasty Revascularization Investigators (BARI). Five-year clinical and functional outcome comparing bypass surgery and angioplasty in patients with multivessel coronary disease. JAMA. 1997;277:715-721.
23. Henderson RA, Pocock SJ, Sharp SJ, et al. Longterm results of RITA-1. Lancet. 1998;352:1419-1425.
24. Feit F, Brooks MM, Sopko G, et al. Long-term clinical outcome in the Bypass Angioplasty Revascularization Investigation Registry. Circulation. 2000;101:2795-2802.
25. Keeley EC, Velez CA, O'Neill WW, Safian RD. Long-term clinical outcome and predictors of major adverse cardiac events after percutaneous interventions on saphenous vein grafts. J Am Coll Cardiol. 2001;38:659-665.
26. Kaehler J, Koester R, Billmann W, et al. 13-Year follow-up of the German angioplasty bypass surgery investigation. Eur Heart J. 2005;26:2148-2153.
27. Ischemia Research and Education Foundation. http://www.iref.org/ LTFU_Death_Appendices1_to_8.html. Accessed January 16, 2007.
28. Lee J, Yoshizawa C, Wilkens L, Lee HP. Covariance adjustment of survival curves based on Cox's proportional hazards regression model. Comput Appl Biosci. 1992;8:23-27.
29. Nieto FJ, Coresh J. Adjusting survival curves for confounders. Am J Epidemiol. 1996;143:1059-1068.
30. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41-55.
31. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265-2281.
32. Hunter D. First, gather the data. N Engl J Med. 2006;354:329-331.
33. Higgins TL, Estafanous FG, Loop FD, Beck GJ, Blum JM, Paranandi L. Stratification of morbidity and mortality outcome by preoperative risk factors in coronary artery bypass patients. JAMA. 1992;267:2344-2348.
34. Brener SJ, Lytle BW, Casserly IP, Schneider JP, Topol EJ, Lauer MS. Propensity analysis of long-term survival after surgical or percutaneous revascularization in patients with multivessel coronary artery disease and high-risk features. Circulation. 2004;109:2290-2295.
35. Hattler BG, Madia C, Johnson C, et al. Risk stratification using the Society of Thoracic Surgeons Program. Ann Thorac Surg. 1994;58:1348-1352.
36. Papadimos TJ, Habib RH, Zacharias A, et al. Early efficacy of CABG care delivery in a low procedure-volume community hospital. BMC Surg. 2005;5:10.
37. Nashef SA, Roques F, Michel P, et al. European System for Cardiac Operative Risk Evaluation (EuroSCORE). Eur J Cardiothorac Surg. 1999;16:9-13.
38. Michel P, Roques F, Samer AM, Nashef SAM. Logistic or additive EuroSCORE for high-risk patients? Eur J Cardiothorac Surg. 2003;23:684-687.
39. Grover FL, Shroyer AL, Hammermeister KE. Calculating risk and outcome. Ann Thorac Surg. 1996;62(5 suppl):S6-S11 ().
40. Gao D, Grunwald GK, Rumsfeld JS, Schooley L, MacKenzie T, Shroyer LW. Time-varying risk factors for long-term mortality after coronary artery bypass graft surgery. Ann Thorac Surg. 2006;81:793-799.
41. Nilsson J, Algotsson L, Höglund P, et al. Comparison of 19 pre-operative risk stratification models in open-heart surgery. Eur Heart J. 2006;27:867-874.
42. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 1993;329:1615-1622.
43. Bidstrup BP, Underwood SR, Sapsford RN, et al. Effect of aprotinin (Trasylol) on aorta-coronary bypass graft patency. J Thorac Cardiovasc Surg. 1993; 105:147-153.
44. Lemmer JH Jr, Stanford W, Bonney SL, et al. Aprotinin for coronary bypass operations. J Thorac Cardiovasc Surg. 1994;107:543-553.
45. Havel M, Grabenwoger F, Schneider J, et al. Aprotinin does not decrease early graft patency after coronary artery bypass graft despite reducing postoperative bleeding and use of donated blood. J Thorac Cardiovasc Surg. 1994;107:807-810.
46. US Food and Drug Administration, Center for Drug Evaluation and Research. Trasylol application 020304/ S004: administrative documents/correspondence, medical officer review (part 2, pages 4, 5, 6), January 3, 1997. http://www.fda.gov/cder/foi/nda/98/020304s004.htm. Accessed January 16, 2007.
47. Westaby S, Katsumata T. Aprotinin and vein graft occlusion - the controversy continues. J Thorac Cardiovasc Surg. 1998;116:731-733.
48. Kaul P, Armstrong PW, Chang WC, et al. Longterm mortality of patients with acute myocardial infarction in the United States and Canada. Circulation. 2004;110:1754-1760.
49. Franzosi MG, Santoro E, De Vita C, et al. Ten-year follow-up of the first megatrial testing thrombolytic therapy in patients with acute myocardial infarction. Circulation. 1998;98:2659-2665.
50. Baigent C, Collins R, Appleby P, et al. 10-Year survival among patients with suspected acute myocardial infarction in randomized comparison of intravenous streptokinase, oral aspirin, both, or neither. BMJ. 1998;316:1337-1343.
51. Mangano DT, Layug EL, Wallace AW, Tateo IM; for the Multicenter Study of Perioperative Ischemia (McSPI) Research Group. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. N Engl J Med. 1996;335:1713-1720.
52. Mangano DT, Browner WS, Hollenberg M, Li JM, Tateo IM; Study of Perioperative Ischemia (SPI) Research Group. Long-term cardiac prognosis following noncardiac surgery. JAMA. 1992;268:233-239.
53. Browner WS, Li JM, Mangano DT; SPI Research Group. In-hospital and long-term mortality in male veterans following noncardiac surgery. JAMA. 1992;268:228-232.
54. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342:1887-1892.
55. US Food and Drug Administration. Report on the performance of drug and biologics firms in conducting postmarketing commitment studies; availability. Fed Regist. 2006;71:10978-10979.